93 related articles for article (PubMed ID: 15831584)
1. Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation.
Gilbert PB; Sun Y
Biostatistics; 2005 Jul; 6(3):374-94. PubMed ID: 15831584
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials.
Shepherd BE; Gilbert PB; Jemiai Y; Rotnitzky A
Biometrics; 2006 Jun; 62(2):332-42. PubMed ID: 16918897
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.
Gilbert PB; Ackers ML; Berman PW; Francis DP; Popovic V; Hu DJ; Heyward WL; Sinangil F; Shepherd BE; Gurwith M
J Infect Dis; 2005 Sep; 192(6):974-83. PubMed ID: 16107949
[TBL] [Abstract][Full Text] [Related]
4. A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial.
Mehrotra DV; Li X; Gilbert PB
Biometrics; 2006 Sep; 62(3):893-900. PubMed ID: 16984333
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral therapy for HIV-1 vaccine efficacy trial participants who seroconvert.
Kim HN; Tabet SR; Corey L; Celum CL
Vaccine; 2006 Jan; 24(4):532-9. PubMed ID: 16242816
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
[TBL] [Abstract][Full Text] [Related]
7. Analysis of antiretroviral immunotherapy trials with potentially non-normal and incomplete longitudinal data.
Mogg R; Mehrotra DV
Stat Med; 2007 Feb; 26(3):484-97. PubMed ID: 16625520
[TBL] [Abstract][Full Text] [Related]
8. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness.
Bocket L; Cheret A; Deuffic-Burban S; Choisy P; Gerard Y; de la Tribonnière X; Viget N; Ajana F; Goffard A; Barin F; Mouton Y; Yazdanpanah Y
Antivir Ther; 2005; 10(2):247-54. PubMed ID: 15865219
[TBL] [Abstract][Full Text] [Related]
9. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
10. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
11. Natural polymorphisms in HIV-1 protease: impact on effectiveness of a first-line lopinavir-containing antiretroviral therapy regimen.
Champenois K; Deuffic-Burban S; Cotte L; André P; Choisy P; Ajana F; Bocket L; Yazdanpanah Y
J Med Virol; 2008 Nov; 80(11):1871-9. PubMed ID: 18814256
[TBL] [Abstract][Full Text] [Related]
12. Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types.
Gilbert PB; Self SG; Ashby MA
Biometrics; 1998 Sep; 54(3):799-814. PubMed ID: 9750238
[TBL] [Abstract][Full Text] [Related]
13. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
14. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
[TBL] [Abstract][Full Text] [Related]
15. On modeling the effects of T-cell vaccines on HIV acquisition and disease.
Wick WD
Stat Med; 2008 Oct; 27(23):4805-16. PubMed ID: 18265425
[TBL] [Abstract][Full Text] [Related]
16. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.
Flynn NM; Forthal DN; Harro CD; Judson FN; Mayer KH; Para MF;
J Infect Dis; 2005 Mar; 191(5):654-65. PubMed ID: 15688278
[TBL] [Abstract][Full Text] [Related]
17. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
Resino S; Larrú B; Maria Bellón J; Resino R; de José MI; Navarro M; Léon JA; Ramos JT; Mellado MJ; Muñoz-Fernández MA
BMC Infect Dis; 2006 Jul; 6():107. PubMed ID: 16834769
[TBL] [Abstract][Full Text] [Related]
18. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.
Lampe FC; Gatell JM; Staszewski S; Johnson MA; Pradier C; Gill MJ; de Lazzari E; Dauer B; Youle M; Fontas E; Krentz HB; Phillips AN
Arch Intern Med; 2006 Mar; 166(5):521-8. PubMed ID: 16534038
[TBL] [Abstract][Full Text] [Related]
19. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
Launay O; Duval X; Dalban C; Descamps D; Peytavin G; Certain A; Mouajjah S; Ralaimazava P; Verdon R; Costagliola D; Clavel F;
Antivir Ther; 2006; 11(7):889-99. PubMed ID: 17302251
[TBL] [Abstract][Full Text] [Related]
20. On the analysis of viral load endpoints in HIV vaccine trials.
Hudgens MG; Hoering A; Self SG
Stat Med; 2003 Jul; 22(14):2281-98. PubMed ID: 12854093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
